<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genomics</journal-id><journal-title>BMC Genomics</journal-title><issn pub-type="epub">1471-2164</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2164-9-12</article-id><article-id pub-id-type="pmid">18190704</article-id><article-id pub-id-type="doi">10.1186/1471-2164-9-12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Genetic and genomic analysis modeling of germline <italic>c-MYC </italic>overexpression and cancer susceptibility</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Sol&#x000e9;</surname><given-names>Xavier</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>x.sole@iconcologia.net</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Hern&#x000e1;ndez</surname><given-names>Pilar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>phgutierrez@iconcologia.net</email></contrib><contrib id="A3" contrib-type="author"><name><surname>de Heredia</surname><given-names>Miguel L&#x000f3;pez</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>mlopezheredia@idibell.org</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Armengol</surname><given-names>Llu&#x000ed;s</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>lluis.armengol@crg.es</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Rodr&#x000ed;guez-Santiago</surname><given-names>Benjam&#x000ed;n</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><email>benjamin.rodriguez@upf.edu</email></contrib><contrib id="A6" contrib-type="author"><name><surname>G&#x000f3;mez</surname><given-names>Laia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lgomez@iconcologia.net</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Maxwell</surname><given-names>Christopher A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cmaxwell@iconcologia.net</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Aguil&#x000f3;</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>faguilo@csub.scs.es</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Condom</surname><given-names>Enric</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>ecm@csub.scs.es</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Abril</surname><given-names>Jes&#x000fa;s</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>jabril@idibell.org</email></contrib><contrib id="A11" contrib-type="author"><name><surname>P&#x000e9;rez-Jurado</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><xref ref-type="aff" rid="I9">9</xref><email>luis.perez@upf.edu</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Estivill</surname><given-names>Xavier</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>xavier.estivill@crg.es</email></contrib><contrib id="A13" contrib-type="author"><name><surname>Nunes</surname><given-names>Virginia</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I10">10</xref><email>vnunes@idibell.org</email></contrib><contrib id="A14" contrib-type="author"><name><surname>Capell&#x000e1;</surname><given-names>Gabriel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gcapella@iconcologia.net</email></contrib><contrib id="A15" contrib-type="author"><name><surname>Gruber</surname><given-names>Stephen B</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>sgruber@med.umich.edu</email></contrib><contrib id="A16" corresp="yes" contrib-type="author"><name><surname>Moreno</surname><given-names>V&#x000ed;ctor</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>v.moreno@iconcologia.net</email></contrib><contrib id="A17" corresp="yes" contrib-type="author"><name><surname>Pujana</surname><given-names>Miguel Angel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mapujana@iconcologia.net</email></contrib></contrib-group><aff id="I1"><label>1</label>Bioinformatics and Biostatistics Unit, and Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, L'Hospitalet, Barcelona, Spain</aff><aff id="I2"><label>2</label>Medical and Molecular Genetics Center, IDIBELL, L'Hospitalet, Barcelona, Spain</aff><aff id="I3"><label>3</label>CIBERER-U730, L'Hospitalet, Barcelona, Spain</aff><aff id="I4"><label>4</label>Genes and Disease Program, Center for Genomic Regulation, Barcelona, Spain</aff><aff id="I5"><label>5</label>Genetics Unit, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain</aff><aff id="I6"><label>6</label>CIBERER-U735, Barcelona, Spain</aff><aff id="I7"><label>7</label>Department of Urology, Bellvitge Hospital University, IDIBELL, L'Hospitalet, Barcelona, Spain</aff><aff id="I8"><label>8</label>Department of Pathology, Bellvitge Hospital University, IDIBELL, L'Hospitalet, Barcelona, Spain</aff><aff id="I9"><label>9</label>Program in Molecular Medicine and Genetics, Vall d'Hebron University Hospital, Barcelona, Spain</aff><aff id="I10"><label>10</label>Genetic Unit, Department of Physiology II, University of Barcelona, Barcelona, Spain</aff><aff id="I11"><label>11</label>Departments of Epidemiology, Internal Medicine and Human Genetics, University of Michigan, Ann Arbor, Michigan, USA</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>11</day><month>1</month><year>2008</year></pub-date><volume>9</volume><fpage>12</fpage><lpage>12</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2164/9/12"/><history><date date-type="received"><day>2</day><month>8</month><year>2007</year></date><date date-type="accepted"><day>11</day><month>1</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Sol&#x000e9; et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Sol&#x000e9; et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Sol&#x000e9; Xavier x.sole@iconcologia.net </dc:author><dc:title> Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Genomics 9(1): 12-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2164(2008)9:1&#x0003c;12&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2164</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Germline genetic variation is associated with the differential expression of many human genes. The phenotypic effects of this type of variation may be important when considering susceptibility to common genetic diseases. Three regions at 8q24 have recently been identified to independently confer risk of prostate cancer. Variation at 8q24 has also recently been associated with risk of breast and colorectal cancer. However, none of the risk variants map at or relatively close to known genes, with <italic>c-MYC </italic>mapping a few hundred kilobases distally.</p></sec><sec><title>Results</title><p>This study identifies cis-regulators of germline <italic>c-MYC </italic>expression in immortalized lymphocytes of HapMap individuals. Quantitative analysis of <italic>c-MYC </italic>expression in normal prostate tissues suggests an association between overexpression and variants in Region 1 of prostate cancer risk. Somatic <italic>c-MYC </italic>overexpression correlates with prostate cancer progression and more aggressive tumor forms, which was also a pathological variable associated with Region 1. Expression profiling analysis and modeling of transcriptional regulatory networks predicts a functional association between MYC and the prostate tumor suppressor KLF6. Analysis of MYC/Myc-driven cell transformation and tumorigenesis substantiates a model in which MYC overexpression promotes transformation by down-regulating <italic>KLF6</italic>. In this model, a feedback loop through E-cadherin down-regulation causes further transactivation of <italic>c-MYC</italic>.</p></sec><sec><title>Conclusion</title><p>This study proposes that variation at putative 8q24 cis-regulator(s) of transcription can significantly alter germline <italic>c-MYC </italic>expression levels and, thus, contribute to prostate cancer susceptibility by down-regulating the prostate tumor suppressor <italic>KLF6 </italic>gene.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Risk of human cancer associated with genetic variation at chromosome 8q24 was first described for prostate cancer in individuals with European ancestry and in African Americans (Risk Region 1) [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. This association was stronger for more aggressive tumor forms [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>] and for earlier age at diagnosis in African Americans [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Differences in allele prevalences could account for the higher incidence of prostate cancer in particular populations such as African-Americans [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Subsequently, 8q24 has been associated with risk of prostate cancer by two extra independent regions [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>] and in risk of breast and colorectal cancer by variation partially overlapping with prostate cancer risk [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. In particular, Haiman <italic>et al.</italic>[<xref ref-type="bibr" rid="B12">12</xref>] first noted the existence of common risk variants for breast and colorectal cancer at 8q24. These observations suggest that multiple cancer genes may exist at 8q24 or, alternatively, that risk variants converge on a common biological mechanism [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>In these studies risk variants did not map to known genes, with few ESTs identified in relatively close proximity. A proposed mechanism includes differences in genomic structure that would make the 8q24 region more prone to subsequent somatic amplification [<xref ref-type="bibr" rid="B14">14</xref>]. The <italic>c-MYC </italic>gene is of particular interest in this region because its ectopic expression has been shown to induce prostatic neoplasia [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. Here, we analyze genetic and genomic data to provide evidence of 8q24 cis-regulator(s) of germline <italic>c-MYC </italic>transcription. In addition, genomic data modeling predicts a molecular mechanism linking germline <italic>c-MYC </italic>overexpression and prostate tumorigenesis.</p></sec><sec><title>Results</title><sec><title>Genetic association scan for germline expression differences</title><p>Scanning associations between genetic variation at 8q24 and <italic>c-MYC </italic>gene expression levels in immortalized lymphocytes of HapMap CEU (Utah residents with ancestry from Northern and WesternEurope) and YRI (Yoruba in Ibadan Nigeria) individuals showed the existence of clusters of SNPs with nominal <italic>P </italic>values &#x0003c; 0.05 (Fig. <xref ref-type="fig" rid="F1">1</xref>). To assess clustering significance, we examined the proportion of significant SNPs in genomic windows 2- or 4-fold the average size of linkage disequilibrium blocks in CEUs or YRIs, respectively (~42 kb corresponding to ~66 SNPs in CEUs and ~36 kb corresponding to ~61 SNPs in YRIs). Twenty thousand permutations were performed to evaluate the significance of the observed clustering. One genomic region in CEUs and three regions in YRIs were identified with high density of significant SNPs (Fig. <xref ref-type="fig" rid="F1">1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Genetic association scan for germline <italic>c-MYC </italic>differential expression in CEUs and YRIs. (A) Top panel shows results for individual SNPs and bottom panel shows results for significant SNP density in genomic windows of ~42 kb/~66 SNPs in CEUs. The red horizontal dashed line marks the nominal <italic>P </italic>value of 0.05. Variants associated with risk of breast [9], colorectal [10-13] or prostate [1-8, 24] cancer are marked with dashed lines as indicated in the inset. (B) Top panel shows results for individual SNPs and bottom panel shows results for significant SNP density in genomic windows of ~36 kb/~61 SNPs in YRIs. Linkage disequilibrium (<italic>D'/LOD</italic>) plots are shown at the bottom for YRIs. Region 1 of prostate cancer risk is shown.</p></caption><graphic xlink:href="1471-2164-9-12-1"/></fig><p>Variation at the <italic>c-MYC </italic>locus was observed with a trend in CEUs, which might suggest the existence of cis-regulators in the gene structural elements (blue bar in Fig. <xref ref-type="fig" rid="F1">1A</xref>). Two variants in this region (rs4645943 C and rs16902364 A) are associated with germline differential expression of <italic>c-MYC</italic>. The allele frequencies of these SNPs were reported to differ between prostate cancer cases and controls in different populations (i.e. 87.7% (cases) and 77.7% (controls) in Hawaiians; 96.3% (cases) and 95.1% (controls) in CEUs for rs4645943 C) [<xref ref-type="bibr" rid="B7">7</xref>]. This observation warrants further genetic analysis of the region with regard to prostate cancer risk.</p><p>The scan revealed a possible association between variants in Region 1 of prostate cancer risk and differential germline expression of <italic>c-MYC </italic>(Fig. <xref ref-type="fig" rid="F1">1B</xref>). Several significant SNPs within this region were identified: the most significant were rs7387447, rs10808558 and rs16902176 (<italic>P </italic>values &#x0003c; 0.01). The rs10808558 A allele showed an association with <italic>c-MYC </italic>overexpression in YRIs (expression difference of 0.23 log<sub>2 </sub>units, 95% confidence interval (CI) 0.06 &#x02013; 0.41; <italic>P </italic>= 0.007) and this SNP is in low linkage disequilibrium (LD) with the prostate cancer risk variant rs1447295 (r<sup>2 </sup>= 0.19). Overall, the scan analysis suggests the existence of 8q24 cis-regulators of germline <italic>c-MYC </italic>transcription in lymphocytes, partially overlapping with Region 1 of prostate cancer risk.</p></sec><sec><title>Expression differences in normal prostate tissues</title><p>Given the possible association of Region 1 variants with germline <italic>c-MYC </italic>overexpression in immortalized lymphocytes of HapMap individuals, we next examined expression differences in normal prostate tissues. For this analysis we used 54 previously characterized normal prostate tissue samples [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>] and a real-time qRT-PCR protocol developed for prostate samples [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. Genotyping the prostate cancer-associated rs1447295 variant in these samples identified six heterozygotes harboring the risk allele A (CA genotypes). No significant age differences were found between donors harboring the two different genotypes (CA versus CC; no AA homozygotes were identified). Quantitative RT-PCR study using three gene references (<italic>18S</italic>, <italic>ALAS1 </italic>and <italic>TBP</italic>) identified significant <italic>c-MYC </italic>overexpression in samples harboring the risk allele relative to CC homozygotes (n = 26) (Wilcoxon rank sum test <italic>P </italic>= 0.004) (Fig. <xref ref-type="fig" rid="F2">2A</xref>). In addition, no evidence of allele-specific amplification in tumors arising in CA individuals was observed (not shown). These results suggest the involvement of germline <italic>c-MYC </italic>overexpression in prostate cancer susceptibility.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Analysis of <italic>c-MYC </italic>expression in normal and prostate cancer tissues. (A) Relative expression differences of <italic>c-MYC </italic>calculated using three gene references with the following formula: <italic>R </italic>= <italic>F</italic><sub><italic>c</italic>-<italic>MYC </italic></sub>- (<italic>F</italic><sub><italic>TBP </italic></sub>- <italic>F</italic><sub><italic>ALAS</italic>1</sub>) where <italic>F</italic><sub><italic>gene i</italic></sub>= <italic>Ct</italic><sub><italic>gene i </italic></sub>- <italic>Ct</italic><sub>18 <italic>S</italic></sub>. (B) <italic>c-MYC </italic>expression in prostate cancer progression. Mean expression values are marked by a red solid rhombus. (C) <italic>c-MYC </italic>expression association study with Gleason scores.</p></caption><graphic xlink:href="1471-2164-9-12-2"/></fig></sec><sec><title>Germline copy number variants</title><p>As a possible mechanism explaining germline overexpression, we next examined copy number variants (CNVs) at the <italic>c-MYC </italic>locus in CEUs and YRIs, and in 322 unrelated individuals from the Spanish general population using a multiplex ligation-dependent probe amplification (MLPA) assay. This assay identified genomic gains at the <italic>c-MYC </italic>locus at a relatively low frequency in the Spanish general population (&#x0003c; 1%; 2/322) (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). However, analysis of rs1447295 genotypes in these individuals did not reveal association with the risk allele and, importantly, none of the CEUs or YRIs showed CNVs with this assay. Therefore, a CNV including <italic>c-MYC </italic>does not seem to be a major contributor to the risk of prostate cancer and germline <italic>c-MYC </italic>overexpression associated with Region 1. Wong <italic>et al.</italic>[<xref ref-type="bibr" rid="B23">23</xref>] previously described a CNV including <italic>c-MYC </italic>but only with genomic losses. This observation corroborates the structural complexity of 8q24 and opens the possibility that different genomic configurations are associated with risk alleles in Region 1 or other 8q24 regions.</p></sec><sec><title>Gene expression analysis in prostate tumors</title><p>Since Region 1 variants were associated with earlier age at diagnosis and high Gleason scores or aggressive tumor forms [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B24">24</xref>], we examined the expression level of 8q24 genes in primary prostate tumors and their association with clinical and pathological variables. For these analyses, we used a publicly available expression data set containing different prostate cellular populations isolated using laser-capture microdissection [<xref ref-type="bibr" rid="B25">25</xref>].</p><p>Comparison of normal versus neoplastic samples showed differential expression of <italic>c-MYC </italic>(Fig. <xref ref-type="fig" rid="F2">2B</xref>). Specifically, overexpression appears in the more advanced stages of tumorigenesis such as carcinomas and hormone-refractory metastases (<italic>t</italic>-test <italic>P </italic>&#x0003c; 10<sup>-3</sup>). Tomlins <italic>et al.</italic>[<xref ref-type="bibr" rid="B25">25</xref>] previously noted the identification of <italic>c-MYC </italic>in an "overexpressed in progression" signature. The <italic>FAM84B </italic>gene at 8q24 also shows overexpression but mainly at earlier stages (<italic>P </italic>= 0.043 and <italic>P </italic>= 0.002 for intraepithelial neoplasia and carcinomas, respectively), which suggests that <italic>FAM84B </italic>could also be a target of 8q24 somatic amplification. Analysis of Gleason scores showed a trend for <italic>c-MYC </italic>overexpression (ANOVA test <italic>P </italic>= 0.056) (Fig. <xref ref-type="fig" rid="F2">2C</xref>). Association between <italic>c-MYC </italic>overexpression and high-grade prostate tumors was previously noted by Buttyan <italic>et al.</italic>[<xref ref-type="bibr" rid="B26">26</xref>] and Fleming <italic>et al.</italic>[<xref ref-type="bibr" rid="B27">27</xref>]. These observations point to a causal relationship between somatic <italic>c-MYC </italic>overexpression and the more aggressive forms of prostate tumors.</p></sec><sec><title>Expression profiles and modeling of transcriptional regulatory networks</title><p>Transcriptional targets of MYC include many genes that were identified as conferring risk of prostate cancer and/or being somatically mutated in prostate tumors [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. We sought to identify which of these genes, particularly those conferring risk of prostate cancer, could be functionally associated with <italic>c-MYC </italic>by examining the similarity between expression profiles using a data set containing 50 normal tissues and 52 prostate tumors [<xref ref-type="bibr" rid="B30">30</xref>]. This analysis revealed strong correlations between <italic>c-MYC </italic>and the prostate tumor suppressor <italic>Kruppel-like factor 6 (KLF6) </italic>gene (Fig. <xref ref-type="fig" rid="F3">3A</xref>). Correlations were positive for <italic>c-MYC </italic>microarray probes 1973_s_at and 37724_at (Pearson's correlation coefficient (PCC) = 0.65; <italic>P </italic>&#x0003c; 10<sup>-13</sup>) and negative for 1827_s_at (PCC = -0.71; <italic>P </italic>&#x0003c; 10<sup>-15</sup>). Extensive alternative splicing of the <italic>c-MYC </italic>mRNA could account for this difference [<xref ref-type="bibr" rid="B31">31</xref>].</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>Expression profiling and modeling of transcriptional regulatory networks. (A) Transcriptional profiles of <italic>c-MYC </italic>and <italic>KLF6 </italic>in prostate tissues [30] using U95A Affymetrix probes shown in the inset. (B) Integrated transcriptional regulatory networks of MYC and KLF6. Gene function assignment based on GO term annotations and known MYC transcription targets are shown as indicated in the inset.</p></caption><graphic xlink:href="1471-2164-9-12-3"/></fig><p>To determine the molecular consequence of the predicted MYC-KLF6 functional association, we generated models of transcriptional regulatory networks in prostate tissues. Using the ARACNe algorithm [<xref ref-type="bibr" rid="B32">32</xref>] and the 102 hybridizations of Singh <italic>et al.</italic>[<xref ref-type="bibr" rid="B30">30</xref>], we identified 88 and 111 putative transcriptional targets of MYC and KLF6 in this cell type, respectively (Fig. <xref ref-type="fig" rid="F3">3B</xref>). The intersection of these two sets contains 25 genes, which is a much larger number of genes than randomly expected using simulations of equivalent gene sets (empirical <italic>P </italic>&#x0003c; 0.001). Importantly, 16 of these genes contain MYC binding sites at their promoters based on TRANSFAC (eukaryotes transcription factors database) matrices [<xref ref-type="bibr" rid="B33">33</xref>]. In addition, many known MYC targets [<xref ref-type="bibr" rid="B29">29</xref>] were also identified: 22 out of 88 (25%) and 23 out of 111 (20%) of the MYC and KLF6 predicted transcriptional targets, respectively (Fig. <xref ref-type="fig" rid="F3">3B</xref>). Notably, <italic>c-MYC </italic>and <italic>KLF6 </italic>were also directly connected and the <italic>KLF6 </italic>promoter contains three predicted binding sites for MYC (not shown). A 5-gene recurrence predictor of prostate cancer [<xref ref-type="bibr" rid="B34">34</xref>] contains <italic>KLF6</italic>, three common ARACNe-based predictions between MYC and KLF6 (<italic>FOS</italic>, <italic>JUNB </italic>and <italic>ZFP36</italic>), and <italic>PPFIA3</italic>, which is functionally related to another predicted target of KLF6 (<italic>PPFIBP2</italic>) (Fig. <xref ref-type="fig" rid="F3">3B</xref>). These observations further support the role of <italic>KLF6</italic>, <italic>c-MYC </italic>and the ARACNe-based predictions in prostate tumorigenesis.</p><p>Comparison of ARACNe-based predictions with the Tomlins <italic>et al.</italic> data set [<xref ref-type="bibr" rid="B25">25</xref>] identified 13 of the 88 predicted MYC transcriptional targets differentially expressed between normal prostate tissues and androgen-independent metastases (FDR-adjusted <italic>P </italic>values &#x0003c; 0.05). In addition, 20 of the predicted targets were found to be differentially expressed between normal prostate tissues and adenocarcinomas. Notably, ~46&#x02013;40% of these genes (6/13 and 8/20) were also predicted to be direct transcriptional targets of KLF6 by the ARACNe algorithm, which endorses the putative functional association between MYC and KLF6.</p></sec><sec><title>Analysis of MYC/Myc-driven cellular transformation and tumorigenesis</title><p>To evaluate the functional significance of the predicted shared MYC/KLF6 transcriptional targets, we examined expression data derived from a model of MYC-driven cellular transformation of quiescent human mammary epithelial cells and from MMTV-Myc-driven mammary tumors in mice [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Of the 25 predicted common targets, 16 (64%) were found to be differentially expressed in cell transformation of quiescent human mammary epithelial cells (Fig. <xref ref-type="fig" rid="F4">4A</xref>). This proportion is ~2-fold higher than expected by chance taking into account all genes examined in the microarray platform (<italic>&#x003c7;</italic><sup>2</sup>-test <italic>P </italic>= 0.004), which substantiates the identification of true MYC targets. Moreover, 11 of the 16 genes contain MYC binding sites at their promoters. Importantly, <italic>KLF6 </italic>was also identified and showed strong down-regulation in this model (<italic>t</italic>-test <italic>P </italic>values &#x0003c; 10<sup>-3</sup>) (Fig. <xref ref-type="fig" rid="F4">4A</xref>).</p><fig position="float" id="F4"><label>Figure 4</label><caption><p>Expression analysis of predicted MYC/KLF6 transcriptional targets in MYC/Myc-driven cell transformation and tumorigenesis. (A) Results of the analysis of quiescent human mammary epithelial cells [36]. (B) Results of the analysis of MMTV-Myc-driven tumors in mice [35]. Genes (red, up-regulated; green, down-regulated), corresponding microarray probes and two-tailed <italic>t</italic>-test <italic>P </italic>values are shown.</p></caption><graphic xlink:href="1471-2164-9-12-4"/></fig><p>Analysis of MMTV-<italic>Myc</italic>-driven mammary tumors in mice showed consistent results with the analysis of quiescent human mammary epithelial cells. Twelve differentially expressed genes were detected, eight of which coincided with the human genes mentioned above (Fig. <xref ref-type="fig" rid="F4">4B</xref>). Genes that did not overlap between the two studies showed similar trends, for example the human <italic>TGIF </italic>showed a trend for down-regulation (<italic>P </italic>= 0.067) while it was identified as significant in the study of mice tumors (<italic>P </italic>= 0.007). Importantly, this analysis also revealed <italic>Klf6 </italic>down-regulation (<italic>P </italic>= 0.003) (Fig. <xref ref-type="fig" rid="F4">4B</xref>). Overall, the discovery of <italic>KLF6/Klf6 </italic>down-regulation in two different models of MYC/Myc-driven cell transformation supports the hypothesis that <italic>c-MYC </italic>germline overexpression could act as a risk factor for prostate cancer by converging on a molecular mechanism such as the functional inactivation of the <italic>KLF6 </italic>gene or gene product.</p><p>Using the MYC/Myc-driven cell transformation models, we next examined the differential expression of known KLF6 transcriptional targets of relevance to epithelial cancers, E-cadherin (<italic>CDH1 </italic>gene) [<xref ref-type="bibr" rid="B37">37</xref>] and p21 (<italic>CDKN1A</italic>) [<xref ref-type="bibr" rid="B38">38</xref>]. This analysis revealed strong down-regulation of <italic>CDH1 </italic>in the transformation of quiescent human mammary epithelial cells (<italic>P </italic>values &#x0003c; 10<sup>-5</sup>) and a trend in the model of Myc-driven mice tumorigenesis (<italic>P </italic>= 0.088). No significant differences were appreciable for <italic>CDKN1A </italic>or <italic>Cdkn1a</italic>. These observations suggest that KLF6 down-regulation mediated by germline MYC overexpression could promote epithelial neoplasia by down-regulating E-cadherin.</p></sec></sec><sec><title>Discussion</title><p>Combined analysis of genetic and expression data facilitates the identification of transcriptional regulators acting in any part of the genome [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>]. Examination of different ethnic groups reinforces the identification of these regulators but also reveals differences between populations [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>]. Due to their functional and structural complexity, transcriptional regulators are largely undercharacterized. However, it is thought that their genetic variability may be relevant when considering susceptibility to common diseases. Specifically, their causal relationship to cancer is almost unknown since most genetic analyses have been focused on coding regions. Insights into differential germline gene expression and tumorigenesis have been gained mainly from mice models, such as the overexpression of the <italic>RAS </italic>family of genes [<xref ref-type="bibr" rid="B43">43</xref>], <italic>Mad2 </italic>[<xref ref-type="bibr" rid="B44">44</xref>] or <italic>c-MYC </italic>[<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>].</p><p>This study analyzed the hypothesis that variation at 8q24 cis-regulator(s) of transcription could significantly alter germline <italic>c-MYC </italic>expression levels and, thus, contribute to cancer susceptibility. Although the genetic scanning analysis performed is susceptible to false positives, the existence of true cis-regulator(s) is suggested by the identification of clusters of significant SNPs. Although larger sample series are required to draw definitive conclusions, the quantitative analysis of geneexpression in normal prostate tissues supports the model of <italic>c-MYC </italic>overexpression associated with Region 1 of prostate cancer risk. Tissue-specific cis-regulator(s) that correlate with additional cancer risk regions at 8q24 may also exist. In a recent study it was noted that tissue specificity is a critical factor in the transcriptional responsiveness of MYC targets [<xref ref-type="bibr" rid="B47">47</xref>].</p><p>The 8q24 region appears amplified in up to 50% of prostate tumors and <italic>c-MYC </italic>is thought to be the primary target of these amplifications since it is overexpressed in prostate hyperplasia and neoplasia [<xref ref-type="bibr" rid="B25">25</xref>]. Ectopic overexpression of <italic>c-MYC/c-Myc </italic>is sufficient to immortalize human prostate epithelial cells [<xref ref-type="bibr" rid="B17">17</xref>] and has been shown to generate human-like prostate tumors in mice [<xref ref-type="bibr" rid="B16">16</xref>]. In addition, <italic>c-MYC </italic>overexpression in prostate cancer cells enables androgen-independent growth [<xref ref-type="bibr" rid="B48">48</xref>]. These observations lead to suggestions of a dual role for <italic>c-MYC </italic>in prostate cancer. At early stages it would promote proliferation while at later stages it would facilitate androgen-independent growth [<xref ref-type="bibr" rid="B17">17</xref>]. Our study further proposes that germline <italic>c-MYC </italic>overexpression may promote cellular transformation of the normal epithelium and, by extension, risk of prostate cancer by down-regulating the prostate tumor suppressor <italic>KLF6 </italic>gene. This model is hypothetical and mainly based on the application of the ARACNe algorithm, which achieves a reasonable tradeoff between true- and false-positive rates by eliminating the majority of indirect interactions inferred from gene co-expression [<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref>]. Experimental corroboration of the predictions generated in this study is therefore needed, particularly in prostate tissues or cell lines.</p><p>The <italic>KLF6 </italic>gene is inactivated in prostate cancer by loss of heterozygosity and/or by somatic mutations identified in tumors, cell lines and xenografts [<xref ref-type="bibr" rid="B51">51</xref>]. Recent evidence has extended the role of <italic>KLF6 </italic>inactivation to several other neoplastic processes as esophageal carcinomas [<xref ref-type="bibr" rid="B52">52</xref>], glioblastomas [<xref ref-type="bibr" rid="B53">53</xref>], head and neck squamous cell carcinomas [<xref ref-type="bibr" rid="B54">54</xref>], hepatocellular carcinomas [<xref ref-type="bibr" rid="B55">55</xref>], non-small cell lung cancer [<xref ref-type="bibr" rid="B56">56</xref>], ovarian carcinomas [<xref ref-type="bibr" rid="B57">57</xref>] and particularly, with regard to 8q24 risk variants, to colorectal cancer [<xref ref-type="bibr" rid="B58">58</xref>]. A key KLF6 transcriptional target for epithelial neoplasia is E-cadherin (<italic>CDH1 </italic>gene), which is a suppressor of cellular invasion [<xref ref-type="bibr" rid="B37">37</xref>]. KLF6 directly transactivates the <italic>CDH1 </italic>promoter resulting in increased levels of its gene product [<xref ref-type="bibr" rid="B37">37</xref>]. <italic>CDH1 </italic>is genetically inactivated in many human cancers and shows reduced or absent expression in approximately 50% of prostate tumors [<xref ref-type="bibr" rid="B59">59</xref>], playing a critical role in the transition from a noninvasive to an invasive phenotype [<xref ref-type="bibr" rid="B60">60</xref>]. Notably, it has recently been proposed that EphB receptors act as tumor suppressors of colorectal cancer, and possibly breast and prostate cancer, through an E-cadherin-mediated mechanism that compartmentalizes tumor cells in the initial stages of tumorigenesis [<xref ref-type="bibr" rid="B61">61</xref>]. Loss of E-cadherin can result in &#x003b2;-catenin nuclear localization and, as a result, the up-regulation of LEF/TCF-mediated transcriptional targets such as <italic>c-MYC</italic>[<xref ref-type="bibr" rid="B62">62</xref>]. Overall, our study suggests the existence of a transcriptional regulatory circuit that is perturbed in human cancer and which begins with the germline overexpression of <italic>c-MYC</italic>, causing down-regulation of <italic>KLF6 </italic>which then reduces the transactivation of <italic>CDH1</italic>, which in turns feeds <italic>c-MYC </italic>expression through &#x003b2;-catenin and LEF/TCF transcriptional complex activation.</p><p>Variants at 8q24 have been associated with risk of prostate, breast and colorectal cancer [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B63">63</xref>]. Although there are different blocks of linkage disequilibrium that harbor risk variants, cancer clustering might suggests the existence of a common molecular mechanism of susceptibility. Expression analyses in normal prostate, breast and colorectal tissues and examination of association with genotypes are needed to determine the convergence on a common mechanism. Nonetheless, tumor tissue specificity may show dependences on specific, although not fully understood, mechanisms of neoplasia. The ectopic overexpression of <italic>MYC/Myc </italic>in specific cell types of mice promotes breast or prostate tumorigenesis [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B64">64</xref>], while widespread expression produces different types of tumors but with preferential appearance of specific epithelial and non-epithelial origins [<xref ref-type="bibr" rid="B46">46</xref>]. Overexpression of <italic>c-MYC </italic>also constitutes an early event after loss of the <italic>APC </italic>tumor suppressor gene that initiates colorectal cancer [<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B65">65</xref>]. In addition, recent evidence shows that loss of heterozygosity at the <italic>KLF6 </italic>locus contributes to the transition from the compartmentalized carcinoma to the invasive carcinoma, specifically in sporadic colorectal cancer [<xref ref-type="bibr" rid="B66">66</xref>,<xref ref-type="bibr" rid="B67">67</xref>], which might suggest a link with the mechanism of tumor-cells compartmentalization in the initial stages of tumorigenesis mediated by E-cadherin [<xref ref-type="bibr" rid="B61">61</xref>]. Although the predictions generated in this study should be treated with a degree of caution, these observations would agree with the hypothesis of a cancer susceptibility mechanism mediated by <italic>c-MYC </italic>germlineoverexpression.</p></sec><sec><title>Conclusion</title><p>This study proposes that variation at putative 8q24 cis-regulator(s) of transcription can significantly alter germline <italic>c-MYC </italic>expression levels and, thus, contribute to prostate cancer susceptibility by down-regulating the prostate tumor suppressor <italic>KLF6 </italic>gene. We propose a transcriptional regulatory model perturbed in human cancer with a feedback loop for <italic>c-MYC</italic>.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Genetic association analysis</title><p>We analyzed HapMap genotypes and paired expression data recently made available for immortalized lymphocytes from four ethnic groups and including 210 independent individuals in total (60 Utah residents with ancestry from northern and western Europe; 45 Han Chinese in Beijing; 45 Japanese in Tokyo; and 60 Yoruba in Ibadan Nigeria; Gene Expression Omnibus (GEO) record GSE6536) [<xref ref-type="bibr" rid="B42">42</xref>]. Transcriptional differences were scanned between the 128 and 129 Mb of chromosome 8, corresponding to ~1,530 SNPs (NCBI build 35). Scans were performed in R with the SNPassoc package [<xref ref-type="bibr" rid="B68">68</xref>]. The log-additive effects of alleles were examined. Association of genotypes with the variable response (gene expression level) was calculated by fitting linear equations and P values obtained by assessing the change in deviance against the null model. Association analysis between genotypes, downloaded from the HapMap data release 21a, and gene expression levels were performed using the web-software SNPStats [<xref ref-type="bibr" rid="B69">69</xref>]. The <italic>D'/LOD </italic>plots were generated using the Haploview software [<xref ref-type="bibr" rid="B70">70</xref>].</p></sec><sec><title>Microarray gene expression analysis</title><p>Using the HapMap lymphocyte expression data [<xref ref-type="bibr" rid="B42">42</xref>] and the prostate cancer data of Tomlins <italic>et al.</italic>[<xref ref-type="bibr" rid="B25">25</xref>], matrix series were downloaded from GEO references GSE6536 and GSE6099, respectively. Using the Singh <italic>et al.</italic>[<xref ref-type="bibr" rid="B30">30</xref>] raw data, background correction, normalization and averaging of expression values were performed with the robust multi-array average (RMA) algorithm. ARACNe Java [<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref>] was used to model the gene expression regulatory networks of <italic>c-MYC </italic>and <italic>KLF6</italic>. In this analysis, data processing inequality (DPI) tolerance was set to 0.20 and the mutual information (MI) threshold was 0.05. Normalized data sets of MYC/Myc-driven cellular transformation and tumorigenesis were downloaded from the GEO records GSE3151 and GSE3158 [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Gene probes were matched using the NetAffx (Affymetrix) tool and differentially expressed probes were identified by calculating two-tailed <italic>t</italic>-test <italic>P </italic>values.</p></sec><sec><title>Genotyping and quantitative RT-PCR analyses</title><p>Prostate tissue specimens were collected through the Tumor Bank of the Bellvitge University Hospital and the Catalan Institute of Oncology. Genotyping of rs1447295 was performed by direct sequencing of PCR products of genomic DNA using the following forward and reverse primers, respectively: 5'-GAGTTGCACGCCAGACACTA-3' and 5'-TTTCCCATACCCCATTCTGA-3'. Quantitative RT-PCR analysis of <italic>c-MYC </italic>was performed using a protocol previously developed with the LightCycler&#x02122; DNA Master SYBR Green I Kit (Roche Applied Sciences) [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>] and <italic>c-MYC </italic>primers 5'-CAGCTGCTTAGACGCTGGATT-3' and 5'-GTAGAAATACGGCTGCACCGA-3', and <italic>TBP </italic>primers 5'-GAACCACGGCACTGATTTTC-3' and 5'-CACAGCTCCCCACCATATTC-3'. Relative expression differences were calculated using three gene references (<italic>18S</italic>, <italic>ALAS1 </italic>and <italic>TBP</italic>) with the following formula: <italic>R </italic>= <italic>F</italic><sub><italic>c</italic>-<italic>MYC </italic></sub>- (<italic>F</italic><sub><italic>TBP </italic></sub>- <italic>F</italic><sub><italic>ALAS</italic>1</sub>) where <italic>F</italic><sub><italic>gene i </italic></sub>= <italic>Ct</italic><sub><italic>gene i </italic></sub>- <italic>Ct</italic><sub>18 <italic>S</italic></sub>.</p></sec><sec><title>Copy number variant analysis</title><p>MLPA assays were performed following the conventional protocol with 150 ng of DNA, overnight ligation and 32 cycles of PCR. Probes for <italic>c-MYC </italic>were 5'-GGGTTCCCTAAGGGTTGGAGGAGGAACGAGCTAAAACGGAGCT-3' and 5'P-TTTTTGCCCTGCGTGACCAGATCCTCTAGATTGGATCTTGCTGGCAC-3'.</p></sec></sec><sec><title>Authors' contributions</title><p>XS participated in the study design, compiled and analyzed the HapMap data, performed the association analysis and the modeling of transcriptional regulatory networks. PH compiled and analyzed the prostate cancer expression data sets and performed the modeling of transcriptional regulatory networks. FA and EC obtained the tissue specimens. MLH, JA and VN performed the quantitative expression analysis. LA, BRS, LG, LPJ and XE performed the copy number variants analysis. CAM, GC and SBG participated in scientific discussions and helped with the overall interpretation of the data. XS, VM and MAP conceived and designed the study. MAP wrote the original and final versions of the manuscript. All authors read and approved the final version of the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>MLPA analysis of several cancer loci including <italic>c-MYC</italic>. Germline genomic gain at <italic>c-MYC </italic>was identified in a sample (bottom) by comparing relative peak intensities.</p></caption><media xlink:href="1471-2164-9-12-S1.PNG" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors are indebted to all those who provided publicly available raw data used in this contribution. We thank Laura Gonz&#x000e1;lez for technical assistance and to three anonymous reviewers for their helpful criticism. Tissue samples were collected through the Tumor Bank of the Bellvitge University Hospital and the Catalan Institute of Oncology, supported by the Tumor Bank Program and the RTICCC C03/10. This work was also supported by the Catalan Institute of Oncology, the "la Caixa" Foundation (BM05-254-00), the ISCIII (FIS-PI06/0545, RCESP-C03/09 and RTICCC-C03/10) and the Spanish Ministry of Education and Science (SAF-2003/5821 and SAF-2005/00166). CAM is supported by a Beatriu de Pin&#x000f3;s fellowship from the Ag&#x000e8;ncia de Gesti&#x000f3; d'Ajuts Universitaris i de Recerca. MAP is a Ram&#x000f3;n y Cajal Researcher with the Spanish Ministry of Education and Science.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>ML</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Patterson</surname><given-names>N</given-names></name><name><surname>McDonald</surname><given-names>GJ</given-names></name><name><surname>Tandon</surname><given-names>A</given-names></name><name><surname>Waliszewska</surname><given-names>A</given-names></name><name><surname>Penney</surname><given-names>K</given-names></name><name><surname>Steen</surname><given-names>RG</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>John</surname><given-names>EM</given-names></name><name><surname>Oakley-Girvan</surname><given-names>I</given-names></name><name><surname>Whittemore</surname><given-names>AS</given-names></name><name><surname>Cooney</surname><given-names>KA</given-names></name><name><surname>Ingles</surname><given-names>SA</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Reich</surname><given-names>D</given-names></name></person-group><article-title>Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>14068</fpage><lpage>14073</lpage><pub-id pub-id-type="pmid">16945910</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0605832103</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amundadottir</surname><given-names>LT</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Gudmundsson</surname><given-names>J</given-names></name><name><surname>Helgason</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>A</given-names></name><name><surname>Agnarsson</surname><given-names>BA</given-names></name><name><surname>Sigurdsson</surname><given-names>A</given-names></name><name><surname>Benediktsdottir</surname><given-names>KR</given-names></name><name><surname>Cazier</surname><given-names>JB</given-names></name><name><surname>Sainz</surname><given-names>J</given-names></name><name><surname>Jakobsdottir</surname><given-names>M</given-names></name><name><surname>Kostic</surname><given-names>J</given-names></name><name><surname>Magnusdottir</surname><given-names>DN</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Agnarsson</surname><given-names>K</given-names></name><name><surname>Birgisdottir</surname><given-names>B</given-names></name><name><surname>Le Roux</surname><given-names>L</given-names></name><name><surname>Olafsdottir</surname><given-names>A</given-names></name><name><surname>Blondal</surname><given-names>T</given-names></name><name><surname>Andresdottir</surname><given-names>M</given-names></name><name><surname>Gretarsdottir</surname><given-names>OS</given-names></name><name><surname>Bergthorsson</surname><given-names>JT</given-names></name><name><surname>Gudbjartsson</surname><given-names>D</given-names></name><name><surname>Gylfason</surname><given-names>A</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Manolescu</surname><given-names>A</given-names></name><name><surname>Kristjansson</surname><given-names>K</given-names></name><name><surname>Geirsson</surname><given-names>G</given-names></name><name><surname>Isaksson</surname><given-names>H</given-names></name><name><surname>Douglas</surname><given-names>J</given-names></name><name><surname>Johansson</surname><given-names>JE</given-names></name><name><surname>Balter</surname><given-names>K</given-names></name><name><surname>Wiklund</surname><given-names>F</given-names></name><name><surname>Montie</surname><given-names>JE</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Suarez</surname><given-names>BK</given-names></name><name><surname>Ober</surname><given-names>C</given-names></name><name><surname>Cooney</surname><given-names>KA</given-names></name><name><surname>Gronberg</surname><given-names>H</given-names></name><name><surname>Catalona</surname><given-names>WJ</given-names></name><name><surname>Einarsson</surname><given-names>GV</given-names></name><name><surname>Barkardottir</surname><given-names>RB</given-names></name><name><surname>Gulcher</surname><given-names>JR</given-names></name><name><surname>Kong</surname><given-names>A</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><article-title>A common variant associated with prostate cancer in European and African populations</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>652</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">16682969</pub-id><pub-id pub-id-type="doi">10.1038/ng1808</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suuriniemi</surname><given-names>M</given-names></name><name><surname>Agalliu</surname><given-names>I</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Johanneson</surname><given-names>B</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Iwasaki</surname><given-names>L</given-names></name><name><surname>Stanford</surname><given-names>JL</given-names></name><name><surname>Ostrander</surname><given-names>EA</given-names></name></person-group><article-title>Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2007</year><volume>16</volume><fpage>809</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">17416775</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-1049</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Slusser</surname><given-names>JP</given-names></name><name><surname>Hebbring</surname><given-names>SJ</given-names></name><name><surname>Cunningham</surname><given-names>JM</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name><name><surname>Cerhan</surname><given-names>JR</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name></person-group><article-title>Two common chromosome 8q24 variants are associated with increased risk for prostate cancer</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>2944</fpage><lpage>2950</lpage><pub-id pub-id-type="pmid">17409399</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3186</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname><given-names>FR</given-names></name><name><surname>Feigelson</surname><given-names>HS</given-names></name><name><surname>Cox</surname><given-names>DG</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Buring</surname><given-names>J</given-names></name><name><surname>Calle</surname><given-names>EE</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Diver</surname><given-names>WR</given-names></name><name><surname>Dunning</surname><given-names>AM</given-names></name><name><surname>Freedman</surname><given-names>ML</given-names></name><name><surname>Gaziano</surname><given-names>JM</given-names></name><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Hoover</surname><given-names>RN</given-names></name><name><surname>Kaaks</surname><given-names>R</given-names></name><name><surname>Key</surname><given-names>T</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Pike</surname><given-names>MC</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name><name><surname>Travis</surname><given-names>R</given-names></name><name><surname>Virtamo</surname><given-names>J</given-names></name><name><surname>Andriole</surname><given-names>G</given-names></name><name><surname>Gelmann</surname><given-names>E</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name></person-group><article-title>A common 8q24 variant in prostate and breast cancer from a large nested case-control study</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>2951</fpage><lpage>2956</lpage><pub-id pub-id-type="pmid">17409400</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3591</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gudmundsson</surname><given-names>J</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Manolescu</surname><given-names>A</given-names></name><name><surname>Amundadottir</surname><given-names>LT</given-names></name><name><surname>Gudbjartsson</surname><given-names>D</given-names></name><name><surname>Helgason</surname><given-names>A</given-names></name><name><surname>Rafnar</surname><given-names>T</given-names></name><name><surname>Bergthorsson</surname><given-names>JT</given-names></name><name><surname>Agnarsson</surname><given-names>BA</given-names></name><name><surname>Baker</surname><given-names>A</given-names></name><name><surname>Sigurdsson</surname><given-names>A</given-names></name><name><surname>Benediktsdottir</surname><given-names>KR</given-names></name><name><surname>Jakobsdottir</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Blondal</surname><given-names>T</given-names></name><name><surname>Kostic</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Stacey</surname><given-names>SN</given-names></name><name><surname>Mouy</surname><given-names>M</given-names></name><name><surname>Saemundsdottir</surname><given-names>J</given-names></name><name><surname>Backman</surname><given-names>VM</given-names></name><name><surname>Kristjansson</surname><given-names>K</given-names></name><name><surname>Tres</surname><given-names>A</given-names></name><name><surname>Partin</surname><given-names>AW</given-names></name><name><surname>Albers-Akkers</surname><given-names>MT</given-names></name><name><surname>Godino-Ivan Marcos</surname><given-names>J</given-names></name><name><surname>Walsh</surname><given-names>PC</given-names></name><name><surname>Swinkels</surname><given-names>DW</given-names></name><name><surname>Navarrete</surname><given-names>S</given-names></name><name><surname>Isaacs</surname><given-names>SD</given-names></name><name><surname>Aben</surname><given-names>KK</given-names></name><name><surname>Graif</surname><given-names>T</given-names></name><name><surname>Cashy</surname><given-names>J</given-names></name><name><surname>Ruiz-Echarri</surname><given-names>M</given-names></name><name><surname>Wiley</surname><given-names>KE</given-names></name><name><surname>Suarez</surname><given-names>BK</given-names></name><name><surname>Witjes</surname><given-names>JA</given-names></name><name><surname>Frigge</surname><given-names>M</given-names></name><name><surname>Ober</surname><given-names>C</given-names></name><name><surname>Jonsson</surname><given-names>E</given-names></name><name><surname>Einarsson</surname><given-names>GV</given-names></name><name><surname>Mayordomo</surname><given-names>JI</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Catalona</surname><given-names>WJ</given-names></name><name><surname>Barkardottir</surname><given-names>RB</given-names></name><name><surname>Gulcher</surname><given-names>JR</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Kong</surname><given-names>A</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><article-title>Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">17401366</pub-id><pub-id pub-id-type="doi">10.1038/ng1999</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Patterson</surname><given-names>N</given-names></name><name><surname>Freedman</surname><given-names>ML</given-names></name><name><surname>Myers</surname><given-names>SR</given-names></name><name><surname>Pike</surname><given-names>MC</given-names></name><name><surname>Waliszewska</surname><given-names>A</given-names></name><name><surname>Neubauer</surname><given-names>J</given-names></name><name><surname>Tandon</surname><given-names>A</given-names></name><name><surname>Schirmer</surname><given-names>C</given-names></name><name><surname>McDonald</surname><given-names>GJ</given-names></name><name><surname>Greenway</surname><given-names>SC</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Frasco</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>D</given-names></name><name><surname>Pooler</surname><given-names>LC</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Oakley-Girvan</surname><given-names>I</given-names></name><name><surname>Whittemore</surname><given-names>AS</given-names></name><name><surname>Cooney</surname><given-names>KA</given-names></name><name><surname>John</surname><given-names>EM</given-names></name><name><surname>Ingles</surname><given-names>SA</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Reich</surname><given-names>D</given-names></name></person-group><article-title>Multiple regions within 8q24 independently affect risk for prostate cancer</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>638</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">17401364</pub-id><pub-id pub-id-type="doi">10.1038/ng2015</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Orr</surname><given-names>N</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Jacobs</surname><given-names>KB</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Minichiello</surname><given-names>MJ</given-names></name><name><surname>Fearnhead</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Chatterjee</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Welch</surname><given-names>R</given-names></name><name><surname>Staats</surname><given-names>BJ</given-names></name><name><surname>Calle</surname><given-names>EE</given-names></name><name><surname>Feigelson</surname><given-names>HS</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name><name><surname>Rodriguez</surname><given-names>C</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Virtamo</surname><given-names>J</given-names></name><name><surname>Weinstein</surname><given-names>S</given-names></name><name><surname>Schumacher</surname><given-names>FR</given-names></name><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Cancel-Tassin</surname><given-names>G</given-names></name><name><surname>Cussenot</surname><given-names>O</given-names></name><name><surname>Valeri</surname><given-names>A</given-names></name><name><surname>Andriole</surname><given-names>GL</given-names></name><name><surname>Gelmann</surname><given-names>EP</given-names></name><name><surname>Tucker</surname><given-names>M</given-names></name><name><surname>Gerhard</surname><given-names>DS</given-names></name><name><surname>Fraumeni</surname><given-names>JF</given-names><suffix>Jr.</suffix></name><name><surname>Hoover</surname><given-names>R</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name></person-group><article-title>Genome-wide association study of prostate cancer identifies a second risk locus at 8q24</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>645</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">17401363</pub-id><pub-id pub-id-type="doi">10.1038/ng2022</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Pooley</surname><given-names>KA</given-names></name><name><surname>Dunning</surname><given-names>AM</given-names></name><name><surname>Pharoah</surname><given-names>PDP</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Ballinger</surname><given-names>DG</given-names></name><name><surname>Struewing</surname><given-names>JP</given-names></name><name><surname>Morrison</surname><given-names>J</given-names></name><name><surname>Field</surname><given-names>H</given-names></name><name><surname>Luben</surname><given-names>R</given-names></name><name><surname>Wareham</surname><given-names>N</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Healey</surname><given-names>CS</given-names></name><name><surname>Bowman</surname><given-names>R</given-names></name><name><surname>Meyer</surname><given-names>KB</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Kolonel</surname><given-names>LK</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Sangrajrang</surname><given-names>S</given-names></name><name><surname>Gaborieau</surname><given-names>V</given-names></name><name><surname>Odefrey</surname><given-names>F</given-names></name><name><surname>Shen</surname><given-names>CY</given-names></name><name><surname>Wu</surname><given-names>PE</given-names></name><name><surname>Wang</surname><given-names>HC</given-names></name><name><surname>Eccles</surname><given-names>D</given-names></name><name><surname>Evans</surname><given-names>DG</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name><name><surname>Fletcher</surname><given-names>O</given-names></name><name><surname>Johnson</surname><given-names>N</given-names></name><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><name><surname>Bojesen</surname><given-names>SE</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Axelsson</surname><given-names>CK</given-names></name><name><surname>Garcia-Closas</surname><given-names>M</given-names></name><name><surname>Brinton</surname><given-names>L</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Peplonska</surname><given-names>B</given-names></name><name><surname>Nevanlinna</surname><given-names>H</given-names></name><name><surname>Fagerholm</surname><given-names>R</given-names></name><name><surname>Eerola</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>D</given-names></name><name><surname>Yoo</surname><given-names>KY</given-names></name><name><surname>Noh</surname><given-names>DY</given-names></name><name><surname>Ahn</surname><given-names>SH</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Cox</surname><given-names>DG</given-names></name><name><surname>Hall</surname><given-names>P</given-names></name><name><surname>Wedren</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Low</surname><given-names>YL</given-names></name><name><surname>Bogdanova</surname><given-names>N</given-names></name><name><surname>Schurmann</surname><given-names>P</given-names></name><name><surname>Dork</surname><given-names>T</given-names></name><name><surname>Tollenaar</surname><given-names>RAEM</given-names></name><name><surname>Jacobi</surname><given-names>CE</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name><name><surname>Klijn</surname><given-names>JGM</given-names></name><name><surname>Sigurdson</surname><given-names>AJ</given-names></name><name><surname>Doody</surname><given-names>MM</given-names></name><name><surname>Alexander</surname><given-names>BH</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>A</given-names></name><name><surname>Brock</surname><given-names>IW</given-names></name><name><surname>MacPherson</surname><given-names>G</given-names></name><name><surname>Reed</surname><given-names>MWR</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name><name><surname>Goode</surname><given-names>EL</given-names></name><name><surname>Olson</surname><given-names>JE</given-names></name><name><surname>Meijers-Heijboer</surname><given-names>H</given-names></name><name><surname>van den Ouweland</surname><given-names>A</given-names></name><name><surname>Uitterlinden</surname><given-names>A</given-names></name><name><surname>Rivadeneira</surname><given-names>F</given-names></name><name><surname>Milne</surname><given-names>RL</given-names></name><name><surname>Ribas</surname><given-names>G</given-names></name><name><surname>Gonzalez-Neira</surname><given-names>A</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>McCredie</surname><given-names>M</given-names></name><name><surname>Southey</surname><given-names>M</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><name><surname>Schroen</surname><given-names>C</given-names></name><name><surname>Justenhoven</surname><given-names>C</given-names></name><name><surname>Brauch</surname><given-names>H</given-names></name><name><surname>Hamann</surname><given-names>U</given-names></name><name><surname>Ko</surname><given-names>YD</given-names></name><name><surname>Spurdle</surname><given-names>AB</given-names></name><name><surname>Beesley</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Mannermaa</surname><given-names>A</given-names></name><name><surname>Kosma</surname><given-names>VM</given-names></name><name><surname>Kataja</surname><given-names>V</given-names></name><name><surname>Hartikainen</surname><given-names>J</given-names></name><name><surname>Day</surname><given-names>NE</given-names></name><name><surname>Cox</surname><given-names>DR</given-names></name><name><surname>Ponder</surname><given-names>BAJ</given-names></name></person-group><article-title>Genome-wide association study identifies novel breast cancer susceptibility loci</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>1087</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">17529967</pub-id><pub-id pub-id-type="doi">10.1038/nature05887</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>I</given-names></name><name><surname>Webb</surname><given-names>E</given-names></name><name><surname>Carvajal-Carmona</surname><given-names>L</given-names></name><name><surname>Broderick</surname><given-names>P</given-names></name><name><surname>Kemp</surname><given-names>Z</given-names></name><name><surname>Spain</surname><given-names>S</given-names></name><name><surname>Penegar</surname><given-names>S</given-names></name><name><surname>Chandler</surname><given-names>I</given-names></name><name><surname>Gorman</surname><given-names>M</given-names></name><name><surname>Wood</surname><given-names>W</given-names></name><name><surname>Barclay</surname><given-names>E</given-names></name><name><surname>Lubbe</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Sellick</surname><given-names>G</given-names></name><name><surname>Jaeger</surname><given-names>E</given-names></name><name><surname>Hubner</surname><given-names>R</given-names></name><name><surname>Wild</surname><given-names>R</given-names></name><name><surname>Rowan</surname><given-names>A</given-names></name><name><surname>Fielding</surname><given-names>S</given-names></name><name><surname>Howarth</surname><given-names>K</given-names></name><name><surname>Silver</surname><given-names>A</given-names></name><name><surname>Atkin</surname><given-names>W</given-names></name><name><surname>Muir</surname><given-names>K</given-names></name><name><surname>Logan</surname><given-names>R</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name><name><surname>Johnstone</surname><given-names>E</given-names></name><name><surname>Sieber</surname><given-names>O</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>H</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name><name><surname>Cazier</surname><given-names>JB</given-names></name><name><surname>Houlston</surname><given-names>R</given-names></name></person-group><article-title>A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>984</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">17618284</pub-id><pub-id pub-id-type="doi">10.1038/ng2085</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zanke</surname><given-names>BW</given-names></name><name><surname>Greenwood</surname><given-names>CMT</given-names></name><name><surname>Rangrej</surname><given-names>J</given-names></name><name><surname>Kustra</surname><given-names>R</given-names></name><name><surname>Tenesa</surname><given-names>A</given-names></name><name><surname>Farrington</surname><given-names>SM</given-names></name><name><surname>Prendergast</surname><given-names>J</given-names></name><name><surname>Olschwang</surname><given-names>S</given-names></name><name><surname>Chiang</surname><given-names>T</given-names></name><name><surname>Crowdy</surname><given-names>E</given-names></name><name><surname>Ferretti</surname><given-names>V</given-names></name><name><surname>Laflamme</surname><given-names>P</given-names></name><name><surname>Sundararajan</surname><given-names>S</given-names></name><name><surname>Roumy</surname><given-names>S</given-names></name><name><surname>Olivier</surname><given-names>JF</given-names></name><name><surname>Robidoux</surname><given-names>F</given-names></name><name><surname>Sladek</surname><given-names>R</given-names></name><name><surname>Montpetit</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>P</given-names></name><name><surname>Bezieau</surname><given-names>S</given-names></name><name><surname>O'Shea</surname><given-names>AM</given-names></name><name><surname>Zogopoulos</surname><given-names>G</given-names></name><name><surname>Cotterchio</surname><given-names>M</given-names></name><name><surname>Newcomb</surname><given-names>P</given-names></name><name><surname>McLaughlin</surname><given-names>J</given-names></name><name><surname>Younghusband</surname><given-names>B</given-names></name><name><surname>Green</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Porteous</surname><given-names>MEM</given-names></name><name><surname>Campbell</surname><given-names>H</given-names></name><name><surname>Blanche</surname><given-names>H</given-names></name><name><surname>Sahbatou</surname><given-names>M</given-names></name><name><surname>Tubacher</surname><given-names>E</given-names></name><name><surname>Bonaiti-Pellie</surname><given-names>C</given-names></name><name><surname>Buecher</surname><given-names>B</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Kury</surname><given-names>S</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Potter</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Dunlop</surname><given-names>MG</given-names></name></person-group><article-title>Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>989</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">17618283</pub-id><pub-id pub-id-type="doi">10.1038/ng2089</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Yamamato</surname><given-names>J</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Wu</surname><given-names>AH</given-names></name><name><surname>Reich</surname><given-names>D</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name></person-group><article-title>A common genetic risk factor for colorectal and prostate cancer</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>954</fpage><lpage>956</lpage><pub-id pub-id-type="pmid">17618282</pub-id><pub-id pub-id-type="doi">10.1038/ng2098</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gruber</surname><given-names>SB</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><name><surname>Rozek</surname><given-names>LS</given-names></name><name><surname>Rennert</surname><given-names>HS</given-names></name><name><surname>Lejbkowicz</surname><given-names>F</given-names></name><name><surname>Bonner</surname><given-names>JD</given-names></name><name><surname>Greenson</surname><given-names>JK</given-names></name><name><surname>Giordano</surname><given-names>TJ</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name></person-group><article-title>Genetic Variation in 8q24 Associated with Risk of Colorectal Cancer</article-title><source>Cancer Biol Ther</source><year>2007</year><volume>6</volume><pub-id pub-id-type="pmid">17630503</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Slezak</surname><given-names>JM</given-names></name><name><surname>Lieber</surname><given-names>MM</given-names></name><name><surname>Bostwick</surname><given-names>DG</given-names></name><name><surname>Bergstralh</surname><given-names>EJ</given-names></name><name><surname>Jenkins</surname><given-names>RB</given-names></name></person-group><article-title>Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><fpage>1574</fpage><lpage>1580</lpage><pub-id pub-id-type="pmid">10491435</pub-id><pub-id pub-id-type="doi">10.1093/jnci/91.18.1574</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Fernandez</surname><given-names>S</given-names></name><name><surname>Stien</surname><given-names>X</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Love</surname><given-names>HD</given-names></name><name><surname>Lau</surname><given-names>YF</given-names></name><name><surname>Roberts</surname><given-names>RL</given-names></name><name><surname>Hayward</surname><given-names>SW</given-names></name></person-group><article-title>Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype</article-title><source>Prostate</source><year>2005</year><volume>63</volume><fpage>369</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">15937962</pub-id><pub-id pub-id-type="doi">10.1002/pros.20200</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellwood-Yen</surname><given-names>K</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Wongvipat</surname><given-names>J</given-names></name><name><surname>Iruela-Arispe</surname><given-names>ML</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Matusik</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>GV</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><article-title>Myc-driven murine prostate cancer shares molecular features with human prostate tumors</article-title><source>Cancer Cell</source><year>2003</year><volume>4</volume><fpage>223</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">14522256</pub-id><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00197-1</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gil</surname><given-names>J</given-names></name><name><surname>Kerai</surname><given-names>P</given-names></name><name><surname>Lleonart</surname><given-names>M</given-names></name><name><surname>Bernard</surname><given-names>D</given-names></name><name><surname>Cigudosa</surname><given-names>JC</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name><name><surname>Carnero</surname><given-names>A</given-names></name><name><surname>Beach</surname><given-names>D</given-names></name></person-group><article-title>Immortalization of primary human prostate epithelial cells by c-Myc</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>2179</fpage><lpage>2185</lpage><pub-id pub-id-type="pmid">15781629</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-4030</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Zaera</surname><given-names>M</given-names></name><name><surname>Abril</surname><given-names>J</given-names></name><name><surname>Gonzalez</surname><given-names>L</given-names></name><name><surname>Aguilo</surname><given-names>F</given-names></name><name><surname>Condom</surname><given-names>E</given-names></name><name><surname>Nadal</surname><given-names>M</given-names></name><name><surname>Nunes</surname><given-names>V</given-names></name></person-group><article-title>Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients</article-title><source>Mutat Res</source><year>2006</year><volume>595</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">16472830</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nadal</surname><given-names>M</given-names></name><name><surname>Pera</surname><given-names>G</given-names></name><name><surname>Pujadas</surname><given-names>J</given-names></name><name><surname>Abril</surname><given-names>J</given-names></name><name><surname>Gonzalez</surname><given-names>L</given-names></name><name><surname>Aguilo</surname><given-names>F</given-names></name><name><surname>Condom</surname><given-names>E</given-names></name><name><surname>Gomez-Zaera</surname><given-names>M</given-names></name><name><surname>Nunes</surname><given-names>V</given-names></name></person-group><article-title>Aneuploidy of chromosome Y in prostate tumors and seminal vesicles: A possible sign of aging rather than an indicator of carcinogenesis?</article-title><source>Mol Carcinog</source><year>2007</year><volume>46</volume><fpage>543</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">17295237</pub-id><pub-id pub-id-type="doi">10.1002/mc.20301</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linja</surname><given-names>MJ</given-names></name><name><surname>Savinainen</surname><given-names>KJ</given-names></name><name><surname>Saramaki</surname><given-names>OR</given-names></name><name><surname>Tammela</surname><given-names>TL</given-names></name><name><surname>Vessella</surname><given-names>RL</given-names></name><name><surname>Visakorpi</surname><given-names>T</given-names></name></person-group><article-title>Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3550</fpage><lpage>3555</lpage><pub-id pub-id-type="pmid">11325816</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Savinainen</surname><given-names>KJ</given-names></name><name><surname>Linja</surname><given-names>MJ</given-names></name><name><surname>Saramaki</surname><given-names>OR</given-names></name><name><surname>Tammela</surname><given-names>TL</given-names></name><name><surname>Chang</surname><given-names>GT</given-names></name><name><surname>Brinkmann</surname><given-names>AO</given-names></name><name><surname>Visakorpi</surname><given-names>T</given-names></name></person-group><article-title>Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer</article-title><source>Br J Cancer</source><year>2004</year><volume>90</volume><fpage>1041</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">14997205</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6601648</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohl</surname><given-names>F</given-names></name><name><surname>Jung</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Stephan</surname><given-names>C</given-names></name><name><surname>Rabien</surname><given-names>A</given-names></name><name><surname>Burkhardt</surname><given-names>M</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>Kristiansen</surname><given-names>G</given-names></name><name><surname>Loening</surname><given-names>SA</given-names></name><name><surname>Radonic</surname><given-names>A</given-names></name><name><surname>Jung</surname><given-names>K</given-names></name></person-group><article-title>Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?</article-title><source>J Mol Med</source><year>2005</year><volume>83</volume><fpage>1014</fpage><lpage>1024</lpage><pub-id pub-id-type="pmid">16211407</pub-id><pub-id pub-id-type="doi">10.1007/s00109-005-0703-z</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>KK</given-names></name><name><surname>deLeeuw</surname><given-names>RJ</given-names></name><name><surname>Dosanjh</surname><given-names>NS</given-names></name><name><surname>Kimm</surname><given-names>LR</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Horsman</surname><given-names>DE</given-names></name><name><surname>MacAulay</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>RT</given-names></name><name><surname>Brown</surname><given-names>CJ</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><name><surname>Lam</surname><given-names>WL</given-names></name></person-group><article-title>A comprehensive analysis of common copy-number variations in the human genome</article-title><source>Am J Hum Genet</source><year>2007</year><volume>80</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">17160897</pub-id><pub-id pub-id-type="doi">10.1086/510560</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Severi</surname><given-names>G</given-names></name><name><surname>Hayes</surname><given-names>VM</given-names></name><name><surname>Padilla</surname><given-names>EJ</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Southey</surname><given-names>MC</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name></person-group><article-title>The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2007</year><volume>16</volume><fpage>610</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">17372260</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0872</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>JT</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Shah</surname><given-names>RB</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><article-title>Integrative molecular concept modeling of prostate cancer progression</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17173048</pub-id><pub-id pub-id-type="doi">10.1038/ng1935</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buttyan</surname><given-names>R</given-names></name><name><surname>Sawczuk</surname><given-names>IS</given-names></name><name><surname>Benson</surname><given-names>MC</given-names></name><name><surname>Siegal</surname><given-names>JD</given-names></name><name><surname>Olsson</surname><given-names>CA</given-names></name></person-group><article-title>Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers</article-title><source>Prostate</source><year>1987</year><volume>11</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">2446300</pub-id><pub-id pub-id-type="doi">10.1002/pros.2990110405</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>WH</given-names></name><name><surname>Hamel</surname><given-names>A</given-names></name><name><surname>MacDonald</surname><given-names>R</given-names></name><name><surname>Ramsey</surname><given-names>E</given-names></name><name><surname>Pettigrew</surname><given-names>NM</given-names></name><name><surname>Johnston</surname><given-names>B</given-names></name><name><surname>Dodd</surname><given-names>JG</given-names></name><name><surname>Matusik</surname><given-names>RJ</given-names></name></person-group><article-title>Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia</article-title><source>Cancer Res</source><year>1986</year><volume>46</volume><fpage>1535</fpage><lpage>1538</lpage><pub-id pub-id-type="pmid">2417706</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Coin</surname><given-names>L</given-names></name><name><surname>Marshall</surname><given-names>M</given-names></name><name><surname>Down</surname><given-names>T</given-names></name><name><surname>Hubbard</surname><given-names>T</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><article-title>A census of human cancer genes</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">14993899</pub-id><pub-id pub-id-type="doi">10.1038/nrc1299</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeller</surname><given-names>KI</given-names></name><name><surname>Jegga</surname><given-names>AG</given-names></name><name><surname>Aronow</surname><given-names>BJ</given-names></name><name><surname>O'Donnell</surname><given-names>KA</given-names></name><name><surname>Dang</surname><given-names>CV</given-names></name></person-group><article-title>An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets</article-title><source>Genome Biol</source><year>2003</year><volume>4</volume><fpage>R69</fpage><pub-id pub-id-type="pmid">14519204</pub-id><pub-id pub-id-type="doi">10.1186/gb-2003-4-10-r69</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Febbo</surname><given-names>PG</given-names></name><name><surname>Ross</surname><given-names>K</given-names></name><name><surname>Jackson</surname><given-names>DG</given-names></name><name><surname>Manola</surname><given-names>J</given-names></name><name><surname>Ladd</surname><given-names>C</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Renshaw</surname><given-names>AA</given-names></name><name><surname>D'Amico</surname><given-names>AV</given-names></name><name><surname>Richie</surname><given-names>JP</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name></person-group><article-title>Gene expression correlates of clinical prostate cancer behavior</article-title><source>Cancer Cell</source><year>2002</year><volume>1</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">12086878</pub-id><pub-id pub-id-type="doi">10.1016/S1535-6108(02)00030-2</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bodescot</surname><given-names>M</given-names></name><name><surname>Brison</surname><given-names>O</given-names></name></person-group><article-title>Characterization of new human c-myc mRNA species produced by alternative splicing</article-title><source>Gene</source><year>1996</year><volume>174</volume><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">8863737</pub-id><pub-id pub-id-type="doi">10.1016/0378-1119(96)00464-7</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname><given-names>K</given-names></name><name><surname>Margolin</surname><given-names>AA</given-names></name><name><surname>Stolovitzky</surname><given-names>G</given-names></name><name><surname>Klein</surname><given-names>U</given-names></name><name><surname>Dalla-Favera</surname><given-names>R</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name></person-group><article-title>Reverse engineering of regulatory networks in human B cells</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>382</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">15778709</pub-id><pub-id pub-id-type="doi">10.1038/ng1532</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matys</surname><given-names>V</given-names></name><name><surname>Fricke</surname><given-names>E</given-names></name><name><surname>Geffers</surname><given-names>R</given-names></name><name><surname>Gossling</surname><given-names>E</given-names></name><name><surname>Haubrock</surname><given-names>M</given-names></name><name><surname>Hehl</surname><given-names>R</given-names></name><name><surname>Hornischer</surname><given-names>K</given-names></name><name><surname>Karas</surname><given-names>D</given-names></name><name><surname>Kel</surname><given-names>AE</given-names></name><name><surname>Kel-Margoulis</surname><given-names>OV</given-names></name><name><surname>Kloos</surname><given-names>DU</given-names></name><name><surname>Land</surname><given-names>S</given-names></name><name><surname>Lewicki-Potapov</surname><given-names>B</given-names></name><name><surname>Michael</surname><given-names>H</given-names></name><name><surname>Munch</surname><given-names>R</given-names></name><name><surname>Reuter</surname><given-names>I</given-names></name><name><surname>Rotert</surname><given-names>S</given-names></name><name><surname>Saxel</surname><given-names>H</given-names></name><name><surname>Scheer</surname><given-names>M</given-names></name><name><surname>Thiele</surname><given-names>S</given-names></name><name><surname>Wingender</surname><given-names>E</given-names></name></person-group><article-title>TRANSFAC: transcriptional regulation, from patterns to profiles</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><fpage>374</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">12520026</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkg108</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glinsky</surname><given-names>GV</given-names></name><name><surname>Glinskii</surname><given-names>AB</given-names></name><name><surname>Stephenson</surname><given-names>AJ</given-names></name><name><surname>Hoffman</surname><given-names>RM</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name></person-group><article-title>Gene expression profiling predicts clinical outcome of prostate cancer</article-title><source>J Clin Invest</source><year>2004</year><volume>113</volume><fpage>913</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">15067324</pub-id><pub-id pub-id-type="doi">10.1172/JCI200420032</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bild</surname><given-names>AH</given-names></name><name><surname>Yao</surname><given-names>G</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Potti</surname><given-names>A</given-names></name><name><surname>Chasse</surname><given-names>D</given-names></name><name><surname>Joshi</surname><given-names>MB</given-names></name><name><surname>Harpole</surname><given-names>D</given-names></name><name><surname>Lancaster</surname><given-names>JM</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Olson</surname><given-names>JA</given-names><suffix>Jr.</suffix></name><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Dressman</surname><given-names>HK</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name></person-group><article-title>Oncogenic pathway signatures in human cancers as a guide to targeted therapies</article-title><source>Nature</source><year>2006</year><volume>439</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">16273092</pub-id><pub-id pub-id-type="doi">10.1038/nature04296</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Ishida</surname><given-names>S</given-names></name><name><surname>Pittman</surname><given-names>J</given-names></name><name><surname>Dressman</surname><given-names>H</given-names></name><name><surname>Bild</surname><given-names>A</given-names></name><name><surname>Kloos</surname><given-names>M</given-names></name><name><surname>D'Amico</surname><given-names>M</given-names></name><name><surname>Pestell</surname><given-names>RG</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name></person-group><article-title>Gene expression phenotypic models that predict the activity of oncogenic pathways</article-title><source>Nat Genet</source><year>2003</year><volume>34</volume><fpage>226</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">12754511</pub-id><pub-id pub-id-type="doi">10.1038/ng1167</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DiFeo</surname><given-names>A</given-names></name><name><surname>Narla</surname><given-names>G</given-names></name><name><surname>Camacho-Vanegas</surname><given-names>O</given-names></name><name><surname>Nishio</surname><given-names>H</given-names></name><name><surname>Rose</surname><given-names>SL</given-names></name><name><surname>Buller</surname><given-names>RE</given-names></name><name><surname>Friedman</surname><given-names>SL</given-names></name><name><surname>Walsh</surname><given-names>MJ</given-names></name><name><surname>Martignetti</surname><given-names>JA</given-names></name></person-group><article-title>E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>6026</fpage><lpage>6031</lpage><pub-id pub-id-type="pmid">16702959</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209611</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narla</surname><given-names>G</given-names></name><name><surname>Kremer-Tal</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Kelley</surname><given-names>K</given-names></name><name><surname>Tarocchi</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>SL</given-names></name></person-group><article-title>In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>4428</fpage><lpage>4434</lpage><pub-id pub-id-type="pmid">17297474</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1210223</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>VG</given-names></name><name><surname>Spielman</surname><given-names>RS</given-names></name></person-group><article-title>The genetics of variation in gene expression</article-title><source>Nat Genet</source><year>2002</year><volume>32 Suppl</volume><fpage>522</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">12454648</pub-id><pub-id pub-id-type="doi">10.1038/ng1036</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buckland</surname><given-names>PR</given-names></name></person-group><article-title>Allele-specific gene expression differences in humans</article-title><source>Hum Mol Genet</source><year>2004</year><volume>13 Spec No 2</volume><fpage>R255</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">15358732</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddh227</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spielman</surname><given-names>RS</given-names></name><name><surname>Bastone</surname><given-names>LA</given-names></name><name><surname>Burdick</surname><given-names>JT</given-names></name><name><surname>Morley</surname><given-names>M</given-names></name><name><surname>Ewens</surname><given-names>WJ</given-names></name><name><surname>Cheung</surname><given-names>VG</given-names></name></person-group><article-title>Common genetic variants account for differences in gene expression among ethnic groups</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">17206142</pub-id><pub-id pub-id-type="doi">10.1038/ng1955</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stranger</surname><given-names>BE</given-names></name><name><surname>Forrest</surname><given-names>MS</given-names></name><name><surname>Dunning</surname><given-names>M</given-names></name><name><surname>Ingle</surname><given-names>CE</given-names></name><name><surname>Beazley</surname><given-names>C</given-names></name><name><surname>Thorne</surname><given-names>N</given-names></name><name><surname>Redon</surname><given-names>R</given-names></name><name><surname>Bird</surname><given-names>CP</given-names></name><name><surname>de Grassi</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Tyler-Smith</surname><given-names>C</given-names></name><name><surname>Carter</surname><given-names>N</given-names></name><name><surname>Scherer</surname><given-names>SW</given-names></name><name><surname>Tavare</surname><given-names>S</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Hurles</surname><given-names>ME</given-names></name><name><surname>Dermitzakis</surname><given-names>ET</given-names></name></person-group><article-title>Relative impact of nucleotide and copy number variation on gene expression phenotypes</article-title><source>Science</source><year>2007</year><volume>315</volume><fpage>848</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">17289997</pub-id><pub-id pub-id-type="doi">10.1126/science.1136678</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mangues</surname><given-names>R</given-names></name><name><surname>Seidman</surname><given-names>I</given-names></name><name><surname>Gordon</surname><given-names>JW</given-names></name><name><surname>Pellicer</surname><given-names>A</given-names></name></person-group><article-title>Overexpression of the N-ras proto-oncogene, not somatic mutational activation, associated with malignant tumors in transgenic mice</article-title><source>Oncogene</source><year>1992</year><volume>7</volume><fpage>2073</fpage><lpage>2076</lpage><pub-id pub-id-type="pmid">1328989</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sotillo</surname><given-names>R</given-names></name><name><surname>Hernando</surname><given-names>E</given-names></name><name><surname>Diaz-Rodriguez</surname><given-names>E</given-names></name><name><surname>Teruya-Feldstein</surname><given-names>J</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Benezra</surname><given-names>R</given-names></name></person-group><article-title>Mad2 overexpression promotes aneuploidy and tumorigenesis in mice</article-title><source>Cancer Cell</source><year>2007</year><volume>11</volume><fpage>9</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">17189715</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2006.10.019</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Pattengale</surname><given-names>PK</given-names></name><name><surname>Leder</surname><given-names>P</given-names></name></person-group><article-title>Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes</article-title><source>Cell</source><year>1984</year><volume>38</volume><fpage>627</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">6488314</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(84)90257-5</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leder</surname><given-names>A</given-names></name><name><surname>Pattengale</surname><given-names>PK</given-names></name><name><surname>Kuo</surname><given-names>A</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Leder</surname><given-names>P</given-names></name></person-group><article-title>Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development</article-title><source>Cell</source><year>1986</year><volume>45</volume><fpage>485</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">3011271</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(86)90280-1</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Blackwell</surname><given-names>TW</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>AW</given-names></name><name><surname>States</surname><given-names>DJ</given-names></name></person-group><article-title>Integration of genome and chromatin structure with gene expression profiles to predict c-MYC recognition site binding and function</article-title><source>PLoS Comput Biol</source><year>2007</year><volume>3</volume><fpage>e63</fpage><pub-id pub-id-type="pmid">17411336</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.0030063</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>D</given-names></name><name><surname>Pourtier-Manzanedo</surname><given-names>A</given-names></name><name><surname>Gil</surname><given-names>J</given-names></name><name><surname>Beach</surname><given-names>DH</given-names></name></person-group><article-title>Myc confers androgen-independent prostate cancer cell growth</article-title><source>J Clin Invest</source><year>2003</year><volume>112</volume><fpage>1724</fpage><lpage>1731</lpage><pub-id pub-id-type="pmid">14660748</pub-id><pub-id pub-id-type="doi">10.1172/JCI200319035</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Margolin</surname><given-names>AA</given-names></name><name><surname>Nemenman</surname><given-names>I</given-names></name><name><surname>Basso</surname><given-names>K</given-names></name><name><surname>Wiggins</surname><given-names>C</given-names></name><name><surname>Stolovitzky</surname><given-names>G</given-names></name><name><surname>Dalla Favera</surname><given-names>R</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name></person-group><article-title>ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context</article-title><source>BMC Bioinformatics</source><year>2006</year><volume>7 Suppl 1</volume><fpage>S7</fpage><pub-id pub-id-type="pmid">16723010</pub-id><pub-id pub-id-type="doi">10.1186/1471-2105-7-S1-S7</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Margolin</surname><given-names>AA</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Lim</surname><given-names>WK</given-names></name><name><surname>Kustagi</surname><given-names>M</given-names></name><name><surname>Nemenman</surname><given-names>I</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name></person-group><article-title>Reverse engineering cellular networks</article-title><source>Nat Protoc</source><year>2006</year><volume>1</volume><fpage>662</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">17406294</pub-id><pub-id pub-id-type="doi">10.1038/nprot.2006.106</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narla</surname><given-names>G</given-names></name><name><surname>Heath</surname><given-names>KE</given-names></name><name><surname>Reeves</surname><given-names>HL</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Giono</surname><given-names>LE</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name><name><surname>Glucksman</surname><given-names>MJ</given-names></name><name><surname>Narla</surname><given-names>J</given-names></name><name><surname>Eng</surname><given-names>FJ</given-names></name><name><surname>Chan</surname><given-names>AM</given-names></name><name><surname>Ferrari</surname><given-names>AC</given-names></name><name><surname>Martignetti</surname><given-names>JA</given-names></name><name><surname>Friedman</surname><given-names>SL</given-names></name></person-group><article-title>KLF6, a candidate tumor suppressor gene mutated in prostate cancer</article-title><source>Science</source><year>2001</year><volume>294</volume><fpage>2563</fpage><lpage>2566</lpage><pub-id pub-id-type="pmid">11752579</pub-id><pub-id pub-id-type="doi">10.1126/science.1066326</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Upadhyay</surname><given-names>S</given-names></name><name><surname>Osada</surname><given-names>M</given-names></name><name><surname>Hoque</surname><given-names>MO</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>F</given-names></name><name><surname>Meltzer</surname><given-names>SJ</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name></person-group><article-title>Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma</article-title><source>Cancer Cell</source><year>2002</year><volume>2</volume><fpage>485</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">12498717</pub-id><pub-id pub-id-type="doi">10.1016/S1535-6108(02)00215-5</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeng</surname><given-names>YM</given-names></name><name><surname>Hsu</surname><given-names>HC</given-names></name></person-group><article-title>KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas</article-title><source>Int J Cancer</source><year>2003</year><volume>105</volume><fpage>625</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">12740910</pub-id><pub-id pub-id-type="doi">10.1002/ijc.11123</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>MS</given-names></name><name><surname>Camacho-Vanegas</surname><given-names>O</given-names></name><name><surname>Fernandez</surname><given-names>Y</given-names></name><name><surname>Narla</surname><given-names>G</given-names></name><name><surname>Difeo</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Kalir</surname><given-names>T</given-names></name><name><surname>Friedman</surname><given-names>SL</given-names></name><name><surname>Schlecht</surname><given-names>NF</given-names></name><name><surname>Genden</surname><given-names>EM</given-names></name><name><surname>Urken</surname><given-names>M</given-names></name><name><surname>Brandwein-Gensler</surname><given-names>M</given-names></name><name><surname>Martignetti</surname><given-names>JA</given-names></name></person-group><article-title>KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma</article-title><source>Int J Cancer</source><year>2007</year><volume>121</volume><fpage>1976</fpage><lpage>1983</lpage><pub-id pub-id-type="pmid">17621627</pub-id><pub-id pub-id-type="doi">10.1002/ijc.22926</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kremer-Tal</surname><given-names>S</given-names></name><name><surname>Reeves</surname><given-names>HL</given-names></name><name><surname>Narla</surname><given-names>G</given-names></name><name><surname>Thung</surname><given-names>SN</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Difeo</surname><given-names>A</given-names></name><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Bioulac-Sage</surname><given-names>P</given-names></name><name><surname>Martignetti</surname><given-names>JA</given-names></name><name><surname>Friedman</surname><given-names>SL</given-names></name></person-group><article-title>Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma</article-title><source>Hepatology</source><year>2004</year><volume>40</volume><fpage>1047</fpage><lpage>1052</lpage><pub-id pub-id-type="pmid">15486921</pub-id><pub-id pub-id-type="doi">10.1002/hep.20460</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>G</given-names></name><name><surname>Uchiyama</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Usami</surname><given-names>N</given-names></name><name><surname>Maeda</surname><given-names>O</given-names></name><name><surname>Kawabe</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>Y</given-names></name><name><surname>Shimokata</surname><given-names>K</given-names></name><name><surname>Sekido</surname><given-names>Y</given-names></name></person-group><article-title>Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>3838</fpage><lpage>3843</lpage><pub-id pub-id-type="pmid">15172991</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0185</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DiFeo</surname><given-names>A</given-names></name><name><surname>Narla</surname><given-names>G</given-names></name><name><surname>Hirshfeld</surname><given-names>J</given-names></name><name><surname>Camacho-Vanegas</surname><given-names>O</given-names></name><name><surname>Narla</surname><given-names>J</given-names></name><name><surname>Rose</surname><given-names>SL</given-names></name><name><surname>Kalir</surname><given-names>T</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Levine</surname><given-names>A</given-names></name><name><surname>Birrer</surname><given-names>MJ</given-names></name><name><surname>Bonome</surname><given-names>T</given-names></name><name><surname>Friedman</surname><given-names>SL</given-names></name><name><surname>Buller</surname><given-names>RE</given-names></name><name><surname>Martignetti</surname><given-names>JA</given-names></name></person-group><article-title>Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>3730</fpage><lpage>3739</lpage><pub-id pub-id-type="pmid">16778100</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0054</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>HL</given-names></name><name><surname>Narla</surname><given-names>G</given-names></name><name><surname>Ogunbiyi</surname><given-names>O</given-names></name><name><surname>Haq</surname><given-names>AI</given-names></name><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Benzeno</surname><given-names>S</given-names></name><name><surname>Hod</surname><given-names>E</given-names></name><name><surname>Harpaz</surname><given-names>N</given-names></name><name><surname>Goldberg</surname><given-names>S</given-names></name><name><surname>Tal-Kremer</surname><given-names>S</given-names></name><name><surname>Eng</surname><given-names>FJ</given-names></name><name><surname>Arthur</surname><given-names>MJ</given-names></name><name><surname>Martignetti</surname><given-names>JA</given-names></name><name><surname>Friedman</surname><given-names>SL</given-names></name></person-group><article-title>Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><fpage>1090</fpage><lpage>1103</lpage><pub-id pub-id-type="pmid">15057748</pub-id><pub-id pub-id-type="doi">10.1053/j.gastro.2004.01.005</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richmond</surname><given-names>PJ</given-names></name><name><surname>Karayiannakis</surname><given-names>AJ</given-names></name><name><surname>Nagafuchi</surname><given-names>A</given-names></name><name><surname>Kaisary</surname><given-names>AV</given-names></name><name><surname>Pignatelli</surname><given-names>M</given-names></name></person-group><article-title>Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>3189</fpage><lpage>3193</lpage><pub-id pub-id-type="pmid">9242448</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Bova</surname><given-names>GS</given-names></name><name><surname>Morton</surname><given-names>RA</given-names></name><name><surname>Bussemakers</surname><given-names>MJ</given-names></name><name><surname>Brooks</surname><given-names>JD</given-names></name><name><surname>Ewing</surname><given-names>CM</given-names></name></person-group><article-title>Molecular biology of prostate cancer progression</article-title><source>Cancer Surv</source><year>1995</year><volume>23</volume><fpage>19</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">7621457</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cortina</surname><given-names>C</given-names></name><name><surname>Palomo-Ponce</surname><given-names>S</given-names></name><name><surname>Iglesias</surname><given-names>M</given-names></name><name><surname>Fernandez-Masip</surname><given-names>JL</given-names></name><name><surname>Vivancos</surname><given-names>A</given-names></name><name><surname>Whissell</surname><given-names>G</given-names></name><name><surname>Huma</surname><given-names>M</given-names></name><name><surname>Peiro</surname><given-names>N</given-names></name><name><surname>Gallego</surname><given-names>L</given-names></name><name><surname>Jonkheer</surname><given-names>S</given-names></name><name><surname>Davy</surname><given-names>A</given-names></name><name><surname>Lloreta</surname><given-names>J</given-names></name><name><surname>Sancho</surname><given-names>E</given-names></name><name><surname>Batlle</surname><given-names>E</given-names></name></person-group><article-title>EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells</article-title><source>Nat Genet</source><year>2007</year><pub-id pub-id-type="pmid">17906625</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>TC</given-names></name><name><surname>Sparks</surname><given-names>AB</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Hermeking</surname><given-names>H</given-names></name><name><surname>Zawel</surname><given-names>L</given-names></name><name><surname>da Costa</surname><given-names>LT</given-names></name><name><surname>Morin</surname><given-names>PJ</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>Identification of c-MYC as a target of the APC pathway</article-title><source>Science</source><year>1998</year><volume>281</volume><fpage>1509</fpage><lpage>1512</lpage><pub-id pub-id-type="pmid">9727977</pub-id><pub-id pub-id-type="doi">10.1126/science.281.5382.1509</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname><given-names>JS</given-names></name></person-group><article-title>Multiple prostate cancer risk variants on 8q24</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>579</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">17460686</pub-id><pub-id pub-id-type="doi">10.1038/ng0507-579</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Cruz</surname><given-names>CM</given-names></name><name><surname>Gunther</surname><given-names>EJ</given-names></name><name><surname>Boxer</surname><given-names>RB</given-names></name><name><surname>Hartman</surname><given-names>JL</given-names></name><name><surname>Sintasath</surname><given-names>L</given-names></name><name><surname>Moody</surname><given-names>SE</given-names></name><name><surname>Cox</surname><given-names>JD</given-names></name><name><surname>Ha</surname><given-names>SI</given-names></name><name><surname>Belka</surname><given-names>GK</given-names></name><name><surname>Golant</surname><given-names>A</given-names></name><name><surname>Cardiff</surname><given-names>RD</given-names></name><name><surname>Chodosh</surname><given-names>LA</given-names></name></person-group><article-title>c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">11175856</pub-id><pub-id pub-id-type="doi">10.1038/84691</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Sancho</surname><given-names>E</given-names></name><name><surname>Verweij</surname><given-names>C</given-names></name><name><surname>de Lau</surname><given-names>W</given-names></name><name><surname>Oving</surname><given-names>I</given-names></name><name><surname>Hurlstone</surname><given-names>A</given-names></name><name><surname>van der Horn</surname><given-names>K</given-names></name><name><surname>Batlle</surname><given-names>E</given-names></name><name><surname>Coudreuse</surname><given-names>D</given-names></name><name><surname>Haramis</surname><given-names>AP</given-names></name><name><surname>Tjon-Pon-Fong</surname><given-names>M</given-names></name><name><surname>Moerer</surname><given-names>P</given-names></name><name><surname>van den Born</surname><given-names>M</given-names></name><name><surname>Soete</surname><given-names>G</given-names></name><name><surname>Pals</surname><given-names>S</given-names></name><name><surname>Eilers</surname><given-names>M</given-names></name><name><surname>Medema</surname><given-names>R</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells</article-title><source>Cell</source><year>2002</year><volume>111</volume><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">12408868</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(02)01014-0</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mukai</surname><given-names>S</given-names></name><name><surname>Hiyama</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Yoshihara</surname><given-names>M</given-names></name><name><surname>Arihiro</surname><given-names>K</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name></person-group><article-title>Involvement of Kruppel-like factor 6 (KLF6) mutation in the development of nonpolypoid colorectal carcinoma</article-title><source>World J Gastroenterol</source><year>2007</year><volume>13</volume><fpage>3932</fpage><lpage>3938</lpage><pub-id pub-id-type="pmid">17663506</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyaki</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Iijima</surname><given-names>T</given-names></name><name><surname>Funata</surname><given-names>N</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name></person-group><article-title>Difference in the role of loss of heterozygosity at 10p15 (KLF6 locus) in colorectal carcinogenesis between sporadic and familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer patients</article-title><source>Oncology</source><year>2006</year><volume>71</volume><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">17347589</pub-id><pub-id pub-id-type="doi">10.1159/000100523</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>JR</given-names></name><name><surname>Armengol</surname><given-names>L</given-names></name><name><surname>Sole</surname><given-names>X</given-names></name><name><surname>Guino</surname><given-names>E</given-names></name><name><surname>Mercader</surname><given-names>JM</given-names></name><name><surname>Estivill</surname><given-names>X</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name></person-group><article-title>SNPassoc: an R package to perform whole genome association studies</article-title><source>Bioinformatics</source><year>2007</year><volume>23</volume><fpage>644</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">17267436</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btm025</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sole</surname><given-names>X</given-names></name><name><surname>Guino</surname><given-names>E</given-names></name><name><surname>Valls</surname><given-names>J</given-names></name><name><surname>Iniesta</surname><given-names>R</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name></person-group><article-title>SNPStats: a web tool for the analysis of association studies</article-title><source>Bioinformatics</source><year>2006</year><volume>22</volume><fpage>1928</fpage><lpage>1929</lpage><pub-id pub-id-type="pmid">16720584</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btl268</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bth457</pub-id></citation></ref></ref-list></back></article> 